La Salvia Anna, Modica Roberta, Spada Francesca, Rossi Roberta Elisa
National Center for Drug Research and Evaluation, National Institute of Health (Istituto Superiore di Sanità, ISS), Rome, Italy.
Endocrinology, Diabetology and Andrology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Endocrine. 2025 Apr;88(1):14-23. doi: 10.1007/s12020-024-04129-z. Epub 2024 Dec 13.
Personalizing care and outcome evaluation are important aims in the field of NEN and nomograms may represent useful tools for clinicians. Of note, gender difference is being progressively more considered in NEN care, as it may also impact on survival. This systematic review aims to describe and analyze the available nomograms on pancreatic NENs (PanNENs) to identify if gender differences are evaluated and if they could impact on patients' management and prognosis.
We performed an electronic-based search using PubMed updated until June 2024, summarizing the available evidence of gender impact on PanNEN survival outcomes as emerges from published nomograms.
34 articles were identified regarding prognostic nomograms in PanNEN fields. The most included variables were age, tumor grade, tumor stage, while only 5 papers (14.7%) included sex as one of the key model variables with a significant impact on patients' prognosis. These 5 studies analyzed a total of 18,920 PanNENs. 3 studies found a significant impact of sex on overall survival (OS), whereas the remaining 2 studies showed no significant impact of sex on OS.
Gender difference is being progressively more considered in PanNEN diagnosis, care and survival. Nomograms represent a potentially useful tool in patients' management and in outcomes prediction in the field of PanNENs. A key role of sex in the prognosis of PanNENs has been found in few models, while definitive conclusions couldn't be drawn. Future studies are needed to finally establish gender impact on PanNEN prognosis.
个性化医疗和疗效评估是神经内分泌肿瘤（NEN）领域的重要目标，列线图可能是临床医生的有用工具。值得注意的是，在NEN治疗中，性别差异越来越受到关注，因为它也可能影响生存率。本系统评价旨在描述和分析现有的胰腺神经内分泌肿瘤（PanNEN）列线图，以确定是否评估了性别差异，以及它们是否会影响患者的管理和预后。
我们使用截至2024年6月更新的PubMed进行电子检索，总结已发表列线图中性别对PanNEN生存结果影响的现有证据。
共检索到34篇关于PanNEN领域预后列线图的文章。最常纳入的变量是年龄、肿瘤分级、肿瘤分期，而只有5篇论文（14.7%）将性别作为对患者预后有显著影响的关键模型变量之一。这5项研究共分析了18920例PanNEN。3项研究发现性别对总生存期（OS）有显著影响，而其余2项研究表明性别对OS无显著影响。
在PanNEN的诊断、治疗和生存中，性别差异越来越受到关注。列线图是PanNEN领域患者管理和预后预测的潜在有用工具。在少数模型中发现了性别在PanNEN预后中的关键作用，但无法得出明确结论。需要进一步的研究来最终确定性别对PanNEN预后的影响。
